MA44551A1 - Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers - Google Patents
Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancersInfo
- Publication number
- MA44551A1 MA44551A1 MA44551A MA44551A MA44551A1 MA 44551 A1 MA44551 A1 MA 44551A1 MA 44551 A MA44551 A MA 44551A MA 44551 A MA44551 A MA 44551A MA 44551 A1 MA44551 A1 MA 44551A1
- Authority
- MA
- Morocco
- Prior art keywords
- peptides
- novel
- immunotherapy
- methods
- cancers
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title 1
- 201000002528 pancreatic cancer Diseases 0.000 title 1
- 208000008443 pancreatic carcinoma Diseases 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000011224 anti-cancer immunotherapy Methods 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Optics & Photonics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Abstract
La présente invention concerne des peptides, des protéines, des acides nucléiques et des cellules à utiliser dans des procédés immunothérapeutiques. L'invention porte en particulier sur l'immunothérapie anticancéreuse. Cette invention concerne en outre des épitopes peptidiques de cellules t tumoraux, seuls ou combinés à d'autres peptides tumoraux, qui peuvent par exemple servir en tant que principes actifs pharmaceutiques de compositions vaccinales qui stimulent une réponse immunitaire antitumorale ou stimulent des cellules t ex vivo ensuite transférées à des patients. Des peptides liés aux molécules du complexe majeur d'histocompatibilité (cmh), ou des peptides en tant que tels, peuvent également être des cibles d'anticorps, des récepteurs de cellules t solubles et d'autres molécules de liaison.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1510771.7A GB201510771D0 (en) | 2015-06-19 | 2015-06-19 | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
PCT/EP2016/063976 WO2016202963A2 (fr) | 2015-06-19 | 2016-06-17 | Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
MA44551A1 true MA44551A1 (fr) | 2021-01-29 |
Family
ID=53784167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA44551A MA44551A1 (fr) | 2015-06-19 | 2016-06-17 | Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers |
Country Status (5)
Country | Link |
---|---|
US (4) | US10385109B2 (fr) |
GB (1) | GB201510771D0 (fr) |
MA (1) | MA44551A1 (fr) |
TW (1) | TWI769135B (fr) |
WO (1) | WO2016202963A2 (fr) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016369519B2 (en) | 2015-12-16 | 2023-04-20 | Gritstone Bio, Inc. | Neoantigen identification, manufacture, and use |
JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
US10346975B2 (en) * | 2016-06-06 | 2019-07-09 | Case Western Reserve University | Computerized analysis of computed tomography (CT) imagery to quantify tumor infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) |
EP4317432A3 (fr) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | Récepteurs de lymphocytes t à appariement amélioré |
DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
WO2018189148A1 (fr) | 2017-04-10 | 2018-10-18 | Immatics Biotechnologies Gmbh | Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse |
US11166640B2 (en) | 2017-06-02 | 2021-11-09 | Apple Inc. | Physiological sampling during predetermined activities |
US10874313B2 (en) | 2017-06-04 | 2020-12-29 | Apple Inc. | Heartrate tracking techniques |
DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
AU2018298884A1 (en) | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
JP7072825B2 (ja) * | 2017-09-13 | 2022-05-23 | 三菱電機ソフトウエア株式会社 | コピー数計測装置、コピー数計測プログラムおよびコピー数計測方法 |
AU2018348165A1 (en) | 2017-10-10 | 2020-05-21 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
CA3083097A1 (fr) | 2017-11-22 | 2019-05-31 | Gritstone Oncology, Inc. | Reduction de la presentation d'epitope de jonction pour des neo-antigenes |
DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
CN108047308A (zh) * | 2018-02-02 | 2018-05-18 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
CN108047309A (zh) * | 2018-02-07 | 2018-05-18 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
CN108250268A (zh) * | 2018-02-08 | 2018-07-06 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
JP7470640B2 (ja) | 2018-02-09 | 2024-04-18 | イマティクス ユーエス,アイエヌシー. | T細胞を製造する方法 |
CN108409832A (zh) * | 2018-03-07 | 2018-08-17 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
CN108218960A (zh) * | 2018-03-07 | 2018-06-29 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
CN108218959A (zh) * | 2018-03-07 | 2018-06-29 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
CN108218961A (zh) * | 2018-03-19 | 2018-06-29 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
CN108440647A (zh) * | 2018-04-02 | 2018-08-24 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
CN108484731A (zh) * | 2018-04-02 | 2018-09-04 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
CN108484730A (zh) * | 2018-04-02 | 2018-09-04 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
CN108250269A (zh) * | 2018-04-02 | 2018-07-06 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
CN108440646A (zh) * | 2018-04-02 | 2018-08-24 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
CN108440648A (zh) * | 2018-04-02 | 2018-08-24 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
CN108440649A (zh) * | 2018-05-31 | 2018-08-24 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
CN108752424A (zh) * | 2018-06-04 | 2018-11-06 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
CN108440650A (zh) * | 2018-06-04 | 2018-08-24 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
CN108440651A (zh) * | 2018-06-08 | 2018-08-24 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
CN108715603A (zh) * | 2018-06-08 | 2018-10-30 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
CN108484732A (zh) * | 2018-06-08 | 2018-09-04 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
EP3897117A1 (fr) | 2018-12-21 | 2021-10-27 | Compass Therapeutics LLC | Souris transgénique exprimant une chaîne légère humaine commune |
CN112675297B (zh) * | 2019-01-29 | 2022-06-24 | 杭州纽安津生物科技有限公司 | 针对靶向药物阿比特龙、恩扎鲁胺、氟他胺、酮康唑聚的多肽疫苗组合及其设计方法 |
US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
WO2020243134A1 (fr) | 2019-05-27 | 2020-12-03 | Immatics US, Inc. | Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive |
US20200384028A1 (en) | 2019-06-06 | 2020-12-10 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
MX2022010461A (es) | 2020-02-24 | 2022-12-13 | Immatics Us Inc | Metodos para expandir linfocitos t para el tratamiento de cancer y neoplasias malignas asociadas. |
DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
WO2021188743A2 (fr) * | 2020-03-20 | 2021-09-23 | Neo7Logix, Llc | Système informatisé d'augmentation immuno-moléculaire basée sur la précision (pbima), procédé et vaccin thérapeutique |
TW202227616A (zh) | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | 分離cd8+選擇t細胞的方法 |
TW202241938A (zh) | 2020-12-31 | 2022-11-01 | 美商英麥提克斯股份有限公司 | Cd8多肽、組合物及其使用方法 |
AU2022269828A1 (en) | 2021-05-05 | 2023-11-23 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
WO2023025851A1 (fr) | 2021-08-24 | 2023-03-02 | Immatics US, Inc. | Sélection de cellules immunitaires à l'aide de complexes peptide-cmh générés par échange de ligands conditionnel |
US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
WO2023081925A1 (fr) | 2021-11-08 | 2023-05-11 | Immatics Biotechnologies Gmbh | Traitement combiné de thérapie cellulaire adoptive et compositions associées |
US20230348548A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
WO2023212691A1 (fr) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Polypeptides récepteurs de tgfβ négatifs dominants, polypeptides cd8, cellules, compositions et leurs méthodes d'utilisation |
WO2023212655A1 (fr) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Polypeptides d'il-12, polypeptides d'il-15, polypeptides d'il-18, polypeptides de cd8, compositions et leurs procédés d'utilisation |
US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
WO2024088176A1 (fr) * | 2022-10-24 | 2024-05-02 | 成都威斯津生物医药科技有限公司 | Molécule d'acide nucléique, protéine de fusion et vaccin à arnm présentant un ligand de recrutement pour améliorer l'effet de présentation d'antigène |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003010327A2 (fr) * | 2001-02-21 | 2003-02-06 | Curagen Corporation | Nouvelles proteines et acides nucleiques les codant |
AU2003223766A1 (en) * | 2002-04-30 | 2003-11-17 | University Of North Carolina At Chapel Hill | Secretion signal vectors |
ATE440107T1 (de) * | 2005-09-05 | 2009-09-15 | Immatics Biotechnologies Gmbh | Tumorassoziierte peptide, die hla klasse i oder ii-moleküle binden, und anti-tumor impfstoffe |
UA103751C2 (ru) * | 2007-07-27 | 2013-11-25 | Имматикс Биотекнолоджис Гмбх | Иммуногенный пептид для иммунотерапии |
JP5475355B2 (ja) | 2009-07-31 | 2014-04-16 | ユニ・チャーム株式会社 | 超音波接合装置及び吸収性物品の製造装置 |
CN102612793A (zh) | 2009-11-19 | 2012-07-25 | 罗伯特·博世有限公司 | 电存储器单元的电压均衡 |
GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
GB201009222D0 (en) | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
US20140065620A1 (en) | 2011-12-29 | 2014-03-06 | Mayo Foundation For Medical Education And Research | Nucleic acids for detecting breast cancer |
AU2013243951A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
-
2015
- 2015-06-19 GB GBGB1510771.7A patent/GB201510771D0/en not_active Ceased
-
2016
- 2016-06-17 TW TW105119200A patent/TWI769135B/zh not_active IP Right Cessation
- 2016-06-17 MA MA44551A patent/MA44551A1/fr unknown
- 2016-06-17 US US15/185,990 patent/US10385109B2/en active Active
- 2016-06-17 WO PCT/EP2016/063976 patent/WO2016202963A2/fr active Application Filing
-
2018
- 2018-05-21 US US15/984,690 patent/US10822390B2/en active Active
- 2018-05-21 US US15/984,681 patent/US10618948B2/en active Active
-
2020
- 2020-01-31 US US16/778,945 patent/US11479594B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20180251519A1 (en) | 2018-09-06 |
TWI769135B (zh) | 2022-07-01 |
WO2016202963A3 (fr) | 2017-02-09 |
US20200157177A1 (en) | 2020-05-21 |
US10385109B2 (en) | 2019-08-20 |
TW201706299A (zh) | 2017-02-16 |
US20160368965A1 (en) | 2016-12-22 |
GB201510771D0 (en) | 2015-08-05 |
US10618948B2 (en) | 2020-04-14 |
US10822390B2 (en) | 2020-11-03 |
US20180251520A1 (en) | 2018-09-06 |
WO2016202963A2 (fr) | 2016-12-22 |
US11479594B2 (en) | 2022-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA44551A1 (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers | |
MA41521A1 (fr) | Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers | |
MA43490A1 (fr) | Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers | |
MA46648A1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers | |
MA44693B1 (fr) | Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du sein et d'autres cancers | |
MA46022B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers | |
MA43719B1 (fr) | Peptide à utiliser en immunothérapie contre le cancer du poumon non à petites cellules et le cancer du poumon à petites cellules | |
MA41393A1 (fr) | Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers | |
MA41520B2 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers | |
MA42381A (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers | |
MA43435B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 25 - mrax5-003) | |
MA43090A1 (fr) | Peptides, combinaisons de peptides et médicaments basés sur les cellules pour l'immunothérapie contre le cancer de la vessie urinaire et d'autres cancers | |
MA43457A1 (fr) | Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers | |
MA42294B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers | |
MA41237B1 (fr) | Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers | |
MA43328A1 (fr) | Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers | |
MA43330A1 (fr) | Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers | |
MA47367B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers | |
MA46913B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers | |
MA41664A1 (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers | |
MA46503A1 (fr) | Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers | |
MA43596A1 (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l'œsophage et d'autres cancers |